Clinical Trials Logo

Hemoglobin SC Disease clinical trials

View clinical trials related to Hemoglobin SC Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06396403 Recruiting - Sickle Cell Disease Clinical Trials

The Role of Red Cell Characteristics, Angiogenesis, Viscosity and Oxygenation in the Pathophysiology of Sickle Cell Related Retinopathy

RAVOS
Start date: June 13, 2023
Phase:
Study type: Observational

Objective: to gain insight in the pathogenesis, to identify biomarkers to recognize patients at risk for proliferative SCR and to investigate its associations with clinical and laboratory characteristics. Endpoints: The investigators will determine the difference in the above named parameters between patients with and without PSCR Study design: This case control study will include adult sickle cell disease patients with the HbSS or HbSC genotype. For both genotypes, 20 patients without sickle cell retinopathy (SCR) and 20 patients with PSCR will be included, resulting in a total of 80 patients. Venous blood samples and retinal imaging scans will be collected for each included patient.

NCT ID: NCT04688411 Recruiting - Sickle Cell Disease Clinical Trials

An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease

Start date: September 28, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate a potential behavioral intervention (MED-Go app). To meet this objective, the researchers will conduct a pilot randomized controlled trial to test the feasibility and acceptability of MED-Go app in adolescents and young adults (AYA) with sickle cell disease (SCD). The long-term goal of this research is to promote medication adherence behavior and improve health outcomes in AYA with SCD.

NCT ID: NCT03805139 Recruiting - Anemia Clinical Trials

Role of Ajwa Derived Polyphenols in Dyslipidaemias

Start date: March 20, 2019
Phase: N/A
Study type: Interventional

World Health Organization report notifies of the escalating global burden of cardiovascular diseases (CVD), projecting that it will become the major worldwide cause of death and disability by 2020. The South Asian countries have the highest rates of CVD globally. It is widely acknowledged that South Asians have 40-60% higher risk of CVD linked to mortality, compared with other populations. Multiple human population studies have established the concentration of high density lipoprotein (HDL) cholesterol as an independent, inverse predictor of the risk of having a cardiovascular event. Furthermore, HDLs have several well-documented functions with the potential to protect against cardiovascular disease. This study trial is designed to find out the role of alternative medicine such as functional food to improve the dyslipidemia and particularly increase the levels of HDL in general population. We expect that the use of Ajwa dates will significantly enhance the level of HDL and reduce cardiovascular events in general population.